Annovis Bio Q3 EPS $(1.63) Misses $(1.09) Estimate
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio reported Q3 losses of $1.63 per share, missing the analyst consensus estimate of $1.09 by 49.54%. This represents a 75.27% increase in losses compared to the same period last year.
November 08, 2023 | 10:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Annovis Bio's Q3 earnings were significantly below analyst estimates, with losses increasing by 75.27% compared to the same period last year.
Annovis Bio's Q3 earnings were significantly below analyst estimates, which is likely to negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100